Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,278 Mln
Revenue (TTM)
$428 Mln
Net Profit (TTM)
$-21 Mln
ROE
-0.1 %
ROCE
-5.1 %
P/E Ratio
--
P/B Ratio
7.4
Industry P/E
--
EV/EBITDA
182.8
Div. Yield
0 %
Debt to Equity
0.5
Book Value
$10.6
EPS
$-0.7
Face value
--
Shares outstanding
29,288,739
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
GeneDx Holdings
| -46.3 | -23.0 | -50.3 | -28.3 | 80.9 | -33.1 | -- |
|
BSE Sensex
| -12.0 | -9.7 | -12.2 | -1.2 | 8.7 | 8.4 | 11.6 |
|
S&P 100
| -8.0 | -5.1 | -7.0 | 16.0 | 21.2 | 12.4 | 13.4 |
|
Company
|
2025
|
2024
|
|---|---|---|
|
GeneDx Holdings
| 69.2 | 2,620.0 |
|
S&P 100
| 18.7 | 29.0 |
|
BSE Sensex
| 9.1 | 8.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
GeneDx Holdings
|
69.8 | 2,278.1 | 427.5 | -21.0 | -4.4 | -7.6 | -- | 7.4 |
| 71.5 | 90,937.7 | 402,067.0 | 1,768.0 | 1.3 | 2.3 | 51.4 | 1.2 | |
| 95.9 | 9,645.1 | 5,935.2 | 566.2 | 18.1 | 25.1 | 17.6 | 4.0 | |
| 493.9 | 110,442.5 | 75,600.0 | 6,784.0 | 16.0 | -159.1 | 17.6 | 293.4 | |
| 263.0 | 21,893.1 | 13,951.7 | 876.5 | 9.5 | 10.5 | 25.2 | 2.5 | |
| 195.3 | 26,624.2 | 2,306.1 | -208.2 | -11.2 | -14.3 | -- | 15.5 | |
| 195.3 | 21,721.2 | 11,035.0 | 992.0 | 13.2 | 14.2 | 22.2 | 3.0 | |
| 200.4 | 17,607.8 | 21,310.0 | 1,407.0 | 16.9 | 33.5 | 12.9 | 4.2 | |
| 200.1 | 12,186.8 | 5,057.8 | 344.0 | 9.2 | 16.9 | 36 | 5.5 | |
| 185.8 | 11,351.1 | 17,364.8 | 1,488.8 | 12.2 | 21.4 | 8.1 | 1.6 |
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also... develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut. Read more
President, CEO & Director
Ms. Katherine A. Stueland
President, CEO & Director
Ms. Katherine A. Stueland
Headquarters
Stamford, CT
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of GeneDx Holdings Corp is $69.84 (NASDAQ) as of 20-Mar-2026 16:00 EDT. GeneDx Holdings Corp has given a return of 80.92% in the last 3 years.
Since, TTM earnings of GeneDx Holdings Corp is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-179.43
|
12.24
|
|
2024
|
-39.69
|
8.46
|
|
2023
|
-0.38
|
0.29
|
|
2022
|
0.00
|
0.01
|
|
2021
|
-0.05
|
0.03
|
The 52-week high and low of GeneDx Holdings Corp are Rs 170.87 and Rs 55.17 as of 21-Mar-2026.
GeneDx Holdings Corp has a market capitalisation of $ 2,278 Mln as on 13-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in GeneDx Holdings Corp, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-3.16
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.